Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: Results from the Juntendo University Schizophrenia Projects (JUSP)

Neuroscience Letters

Volumn 469, Issue 1, 2010, Pages 55-59

  Higa, Masayuki ^a   Ohnuma, Tohru ^a   Maeshima, Hitoshi ^a   Hatano, Tokiko ^a   Hanzawa, Ryo ^a   Shibata, Nobuto ^a   Sakai, Yoshie ^a   Suzuki, Toshihito ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Parkinsonism; RGS2

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOSINE; DIAZEPAM; GUANINE; NEUROLEPTIC AGENT; RGS2 PROTEIN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERSALIVATION; JAPANESE; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOTHERAPY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PARKINSONIAN DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RGS PROTEINS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 72649093911     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.11.043     Document Type: Article

References (27)

1. Al Hadithy A.F., Wilffert B., Bruggeman R., Stewart R.E., Brouwers J.R., Matroos G.E., Hoek H.W., and van Harten P.N. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum. Psychopharmacol. 24 (2009) 123-128
2. Basile V.S., Ozdemir V., Masellis M., Meltzer H.Y., Lieberman J.A., Potkin S.G., Macciardi F.M., Petronis A., and Kennedy J.L. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol. Psychiatry 6 (2001) 230-234
3. Bernstein L.S., Ramineni S., Hague C., Cladman W., Chidiac P., Levey A.I., and Hepler J.R. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J. Biol. Chem. 279 (2004) 21248-21256
4. Caligiuri M.P., Lacro J.P., and Jeste D.V. Incidence and predictors of drug-induced Parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J. Clin. Psychopharmacol. 19 (1999) 322-328
5. Caligiuri M.P., Lacro J.P., Rockwell E., McAdams L.A., and Jeste D.V. Incidence and risk factors for severe tardive dyskinesia in older patients. Br. J. Psychiatry 171 (1997) 148-153
6. Chen C.H., Wei F.C., Koong F.J., and Hsiao K.J. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry 41 (1997) 827-829
7. Davis J.M. Comparative doses and costs of antipsychotic medication. Arch. Gen. Psychiatry 33 (1976) 858-861
8. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., and Ashby Jr. C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15 (1995) 821-829
9. Ertugrul A., Kennedy J.L., Masellis M., Basile V.S., Jayathilake K., and Meltzer H.Y. No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophr. Res. 69 (2004) 301-305
10. Ghavami A., Hunt R.A., Olsen M.A., Zhang J., Smith D.L., Kalgaonkar S., Rahman Z., and Young K.H. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal. 16 (2004) 711-721
11. Greenbaum L., Smith R.C., Rigbi A., Strous R., Teltsh O., Kanyas K., Korner M., Lancet D., Ben-Asher E., and Lerer B. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. Pharmacogenomics J. 9 (2009) 103-110
12. Greenbaum L., Strous R.D., Kanyas K., Merbl Y., Horowitz A., Karni O., Katz E., Kotler M., Olender T., Deshpande S.N., Lancet D., Ben-Asher E., and Lerer B. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet. Genomics 17 (2007) 519-528
13. Guzey C., Scordo M.G., Spina E., Landsem V.M., and Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur. J. Clin. Pharmacol. 63 (2007) 233-241
14. Hollinger S., and Hepler J.R. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev. 54 (2002) 527-559
15. Hori H., Ohmori O., Shinkai T., Kojima H., and Nakamura J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. 105 (2001) 774-778
16. Inada T., Beasley Jr. C.M., Tanaka Y., and Walker D.J. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int. Clin. Psychopharmacol. 18 (2003) 39-48
17. Inada T., Yagi G., and Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr. Res. 57 (2002) 227-238
18. Ingi T., Krumins A.M., Chidiac P., Brothers G.M., Chung S., Snow B.E., Barnes C.A., Lanahan A.A., Siderovski D.P., Ross E.M., Gilman A.G., and Worley P.F. Dynamic regulation of RGS2 suggests a novel mechanism in G-protein signaling and neuronal plasticity. J. Neurosci. 18 (1998) 7178-7188
19. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
20. Lerer B., Segman R.H., Tan E.C., Basile V.S., Cavallaro R., Aschauer H.N., Strous R., Chong S.A., Heresco-Levy U., Verga M., Scharfetter J., Meltzer H.Y., Kennedy J.L., and Macciardi F. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int. J. Neuropsychopharmacol. 8 (2005) 411-425
21. Ohnuma T., Sakai Y., Maeshima H., Hatano T., Hanzawa R., Abe S., Kida S., Shibata N., Suzuki T., and Arai H. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1905-1912
22. Overall JE G.O. The Brief Psychiatry Rating Scale. Psychol. Rep. 10 (1962) 799-812
23. Reynolds G.P. Muscarinic M1 receptors in schizophrenia. Mol. Psychiatry 1 (1996) 364-366
24. Reynolds G.P. Receptor mechanisms in the treatment of schizophrenia. J. Psychopharmacol. 18 (2004) 340-345
25. Rickels K., DeMartinis N., Garcia-Espana F., Greenblatt D.J., Mandos L.A., and Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am. J. Psychiatry 157 (2000) 1973-1979
26. Segman R.H., and Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol. Psychiatry 7 (2002) 137-139
27. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 (1997) 407-418